Format

Send to

Choose Destination
See comment in PubMed Commons below
AIDS. 2010 Sep 10;24(14):2193-200. doi: 10.1097/QAD.0b013e32833ce57d.

Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancy.

Collaborators (120)

Hemvuttiphan J, Wongchai R, Changlor B, Maneekaew A, Jansook K, Bunchaisun S, Achalapong J, Jinasa S, Chart P, Saisawat K, Thongsuk P, Utsaha S, Buranabanjasatean S, Thuenyeanyong N, Kaeha P, Taiyaithieng T, Juntapoon B, Yuthavisuthi P, Wongsrisai R, Chanasit U, Tungtongcha N, Greetanukroh P, Boonrod K, Thongsuwan S, Kanjanavikai P, Kaewsaweat W, Sawatmarn S, Chotivanich N, Thimakam T, Krapunpongsakul N, Asarath C, Wanno R, Yothipitak P, Soontaros S, Chaisiri K, Suwankornsakul W, Thuraset P, Cheawchan A, Phasuk S, Limtrakul A, Thonglo J, Thomyota B, Nakrit A, Lymthavorn P, Rawangban B, Krueduangkam P, Wijitwong T, Leepaiboon K, Poolpat P, Prommas S, Thitathan M, Winaitham S, Pengmark B, Pipatnakulchai S, Khanmali J, Jitmaleerat K, Wongsirikul K, Jarupanich T, Kruenual N, Sukhaphan U, Jitsakulchaidej R, Puarattana N, Pongchaisit W, Pothinukka S, Phomcheam N, Kaengklang S, Varadisai S, Chalasin J, Sookbumrung Y, Raiva W, Kongpanichkul R, Seema C, Bunditwong P, Kapol P, Sabsanong P, Ratchanee B, Bunluesak K, Yaisiri A, Jenpoomjai N, Lianpongsabuddhi P, Thammajitsagul S, Keowkarnkah T, Supong S, Hanyutthapong S, Leelaporn W, Chirayus S, Wannun S, Eawsakul S, Kongthap I, Pinkaew N, Wiriyachoke B, Thanadechworasate C, Satjeanphong P, Katekaraj R, Chakorngowit M, Niamlamul S, Saithong S, Suebchart P, Kanshana S, Koetsawang S, Le Coeur S, McIntosh K, Sukrakanchana PO, Chalermpantmetagul S, Than-in-at K, Taworn Y, Punyati P, Thongkum A, Mongkolwat P, Kaewbundit A, Pongpunyayuen P, Decker L, Lueanyod A, Tanasri S, Chailert S, Yoddee K, Seubmongkolchai R, Chinwong D, Saenchitta P, Sanjoom C.

Abstract

OBJECTIVE:

To evaluate the pharmacokinetics and HIV viral load response following initiation during the third trimester of pregnancy of zidovudine plus standard-dose lopinavir boosted with ritonavir (LPV/r), twice daily, until delivery for the prevention of mother-to-child transmission of HIV.

DESIGN:

Prospective study nested within a multicenter, three-arm, randomized, phase III prevention of mother-to-child transmission of HIV trial in Thailand (PHPT-5, ClinicalTrials.gov Identifier: NCT00409591).

METHODS:

Women randomized to receive 300 mg zidovudine and 400/100 mg LPV/r twice daily from 28 weeks' gestation, or as soon as possible thereafter, until delivery had intensive steady-state 12-h blood sampling performed. LPV/r pharmacokinetic parameters were calculated using noncompartmental analysis. Rules were defined a priori for a LPV/r dose escalation based on the proportion of women with an LPV area under the concentration-time curve (AUC) below 52 microg h/ml (10th percentile for LPV AUC in nonpregnant adults). HIV-1 RNA response was assessed during the third trimester.

RESULTS:

Thirty-eight women were evaluable; at entry, median (range) gestational age was 29 (28-36) weeks, weight 59.5 (45.0-91.6) kg, CD4 cells count 442 (260-1327) cells/microl and HIV-1 RNA viral load 7818 (<40-402 015) copies/ml. Geometric mean (90% confidence interval) LPV AUC, Cmax and Cmin were 64.6 (59.7-69.8) microg h/ml, 8.1 (7.5-8.7) microg/ml and 2.7 (2.4-3.0) microg/ml, respectively. Thirty-one of 38 (81%) women had an LPV AUC above the AUC target. All women had a HIV-1 viral load less than 400 copies/ml at the time of delivery.

CONCLUSION:

A short course of zidovudine plus standard-dose LPV/r initiated during the third trimester of pregnancy achieved adequate LPV exposure and virologic response.

[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Lippincott Williams & Wilkins Icon for PubMed Central
    Loading ...
    Write to the Help Desk